Maistrello I, Grassi G, Bertolino A, Valerio P, Pistollato G, Soverini S
Eur J Clin Pharmacol. 1983;24(2):277-81. doi: 10.1007/BF00613832.
Ninety-six depressed outpatients from 5 centres were given viloxazine 200-400 mg/day. The treatment produced significant clinical improvement as evaluated by the Hamilton Rating Scale for Depression. Thirteen patients dropped-out because of possible side effects. Many untoward symptoms were described by all the patients. To distinguish between illness-related symptoms (IRSs) and potential side effect symptoms (SESs) a new approach was taken, using an algorithm that provides a decision strategy based on the time course both of the symptom and the illness. By this procedure, 90 of the 187 claimed untoward symptoms were identified as IRSs. Of the 97 potential SESs, only 36 were spontaneously volunteered, and the remaining 61 symptoms were elicited on specific questioning. Whenever possible, volunteered potential SESs were assessed to determine the relationship between the drug treatment and the adverse reaction. It was found that only a few instances of gastric disturbance and exacerbation of anxiety were probably viloxazine-related.
来自5个中心的96名门诊抑郁症患者服用了每日200 - 400毫克的维洛沙嗪。根据汉密尔顿抑郁评定量表评估,该治疗产生了显著的临床改善。13名患者因可能的副作用而退出。所有患者都描述了许多不适症状。为了区分疾病相关症状(IRSs)和潜在副作用症状(SESs),采用了一种新方法,使用一种基于症状和疾病的时间进程提供决策策略的算法。通过该程序,187例声称的不适症状中有90例被确定为IRSs。在97例潜在的SESs中,只有36例是患者自发提出的,其余61例症状是在特定询问中引出的。只要有可能,就对患者自发提出的潜在SESs进行评估,以确定药物治疗与不良反应之间的关系。结果发现,只有少数几例胃部不适和焦虑加剧可能与维洛沙嗪有关。